Durvalumab (anti-PD-L1) plus tremelimumab (anti-CTLA-4) is a similar ICI combination that showed significant clinical activity and tolerability for unresectable HCC after sorafenib in a phase I/II study (76). The gene discussed is CTLA4; the disease is hepatocellular carcinoma.